Nucor earnings beat by $0.08, revenue fell short of estimates
BOSTON - Entrada Therapeutics, Inc. (NASDAQ: TRDA), a clinical-stage biopharmaceutical company, today announced the appointment of Maha Radhakrishnan, M.D., to its Board of Directors. Dr. Radhakrishnan’s addition comes as the company is experiencing significant clinical progress, particularly within its Duchenne muscular dystrophy (DMD) programs. The appointment strengthens Entrada’s leadership as it aims to capitalize on opportunities in the biotechnology sector, where established players like Biogen maintain strong market positions with substantial gross profit margins exceeding 75%.
Dr. Radhakrishnan brings a wealth of experience from her tenure as an executive partner at Sofinnova Investments, where she has served since August 2024. Her previous roles include Group Senior Vice President and Chief Medical Officer at Biogen from January 2020 to March 2024, and leadership positions at Sanofi, Bioverativ, Bristol Myers Squibb, UnitedHealth Group, and Cephalon. She is recognized for her expertise in global drug development and has a strong track record in clinical asset diligence and product development. According to InvestingPro data, Biogen maintains a strong financial position with a market capitalization of $19.2 billion and an impressive "GREAT" financial health score, demonstrating the caliber of organizations in Dr. Radhakrishnan’s background.
Dipal Doshi, CEO of Entrada Therapeutics, expressed confidence that Dr. Radhakrishnan’s deep experience will be invaluable as the company advances its DMD programs into patient-focused clinical trials throughout the year. Dr. Radhakrishnan herself commented on the promising Phase 1 safety and target engagement data for Entrada’s therapies, highlighting the urgent need for new treatments for DMD and her commitment to advancing these therapies to patients.
Entrada Therapeutics is focused on developing a new class of intracellular medicines using its proprietary Endosomal Escape Vehicle (EEV™)-therapeutics. The company aims to improve therapeutic index by enabling efficient intracellular delivery of a variety of therapeutics into organs and tissues. Its leading oligonucleotide programs are designed to potentially treat people with Duchenne muscular dystrophy who are amenable to exon skipping.
The company’s forward-looking statements reflect its plans and expectations for future operations, including global Phase 2 clinical studies for its DMD treatment candidates ENTR-601-44, ENTR-601-45, and ENTR-601-50. These statements are based on current beliefs and are subject to risks and uncertainties that could cause actual results to differ materially.
This news article is based on a press release statement from Entrada Therapeutics. For deeper insights into the biotechnology sector and companies like Biogen, InvestingPro offers comprehensive financial analysis, including detailed research reports covering over 1,400 US stocks, with expert insights and key metrics that help investors make informed decisions.
In other recent news, Biogen has reported its first-quarter earnings for 2025, showcasing a revenue of $2.43 billion and an adjusted earnings per share (EPS) of $3.02. This performance exceeded both Canaccord’s and consensus estimates, which anticipated revenues of $2.23 billion. Goldman Sachs maintained a Buy rating for Biogen with a price target of $196, highlighting the strong sales performance of Leqembi, an Alzheimer’s treatment developed with Eisai. However, H.C. Wainwright adjusted its price target for Biogen to $187, citing recent developments around Leqembi but maintaining a Buy rating due to its strong growth. Canaccord also revised its price target to $220 from $265, maintaining a Buy recommendation following Biogen’s robust first-quarter results. Stifel, on the other hand, retained a Hold rating with a $144 price target, noting a solid quarter despite some missed EPS expectations due to a significant transaction. These recent developments reflect a mixed yet cautiously optimistic outlook for Biogen among analysts, with particular attention on its Alzheimer’s treatment portfolio and future pipeline prospects.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.